Recently, the development of protein degraders (protein-degrading compounds) has
prominently progressed. There are two remarkable classes of protein degraders: proteolysis …

Regulation of the human IGF2 gene displays multiple layers of control, which secures a
genetically and epigenetically predetermined gene expression pattern throughout …

Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor
survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major …

Bridged PROTAC is a novel protein complex degrader strategy that exploits the target
protein's binding partner to degrade undruggable proteins by inducing proximity to an E3 …

Transcription factors (TFs) and RNA-binding proteins (RBPs) have long been considered
undruggable, mainly because they lack ligand-binding sites and are equipped with flat and …

Transcription factors play central roles in numerous diseases yet are notoriously challenging
targets for drug development. In this issue of Cell Chemical Biology, Samarasinghe et …

Chemical knockdown of therapeutic targets using proteolysis targeting chimeras (PROTACs)
is a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that …

The development of effective and personalized treatment options for patients with rare
cancers like chordoma is hampered by numerous challenges. Biomarker-guided …

Targeted protein degradation (TPD) represented by proteolysis targeting chimeras
(PROTACs) marks a significant stride in drug discovery. A plethora of innovative …

Highlights•Traditional antibodies block ligand binding or drive Fc effector
functions.•Bifunctional antibodies function through an induced proximity …